



children



an Open Access Journal by MDPI

Global Collaboration in Pediatric Drug Development and Formulation: Toward Better and Safe, and Appropriate Formulation for Children

Guest Editors:

Dr. Jumpei Saito

Pharmaceutical Department,
Neonatal and Reproductive
Medicine, Tokyo 157-8535, Japan

Dr. Akimasa Yamatani

Department of Pharmacy,
National Center for Child Health
and Development, Tokyo, Japan

Dr. Takehisa Hanawa

Faculty of Pharmaceutical
Sciences, Tokyo University of
Science, 2641 Yamazaki, Noda,
Chiba 278-8510, Japan

Deadline for manuscript
submissions:

closed (25 August 2023)

Message from the Guest Editors

Dear Colleagues,

For pediatric patients, the formulations designed for and tested on adults lead to incorrect dosing, poor acceptance, complicated administration practice (i.e., pediatric compounding), and therapeutic failure or adverse events. Enhanced awareness of these issues, children's needs, and evolving regulatory expectations may accelerate the development of age-appropriate pediatric formulation. This Special Issue aims to review and integrate the knowledge and ongoing efforts in the field of pediatric development.

We welcome original research, reviews, opinion papers, editorials, or short communications on the following topics:

- Pediatric drug development;
- Acceptability study in pediatrics;
- Excipients use in pediatric formulations;
- Age-appropriate drug development;
- Issues and challenges in pediatric compounding
- International collaboration on regulation for pediatric drug development
- Advanced technology for pediatric formulation



mdpi.com/si/107123

Special Issue